A proteomic signature for dementia with Lewy bodies

Sid E. O'Bryant, Tanis Jill Ferman, Fan Zhang, James Hall, Otto D Pedraza, Zbigniew K Wszolek, Tori Como, David Julovich, Sravan Mattevada, Leigh A. Johnson, Melissa Edwards, Neill R Graff Radford

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: We sought to determine if a proteomic profile approach developed to detect Alzheimer's disease would distinguish patients with Lewy body disease from normal controls, and if it would distinguish dementia with Lewy bodies (DLB) from Parkinson's disease (PD). Methods: Stored plasma samples were obtained from 145 patients (DLB n = 57, PD without dementia n = 32, normal controls n = 56) enrolled from patients seen in the Behavioral Neurology or Movement Disorders clinics at the Mayo Clinic, Florida. Proteomic assays were conducted and analyzed as per our previously published protocols. Results: In the first step, the proteomic profile distinguished the DLB-PD group from controls with a diagnostic accuracy of 0.97, sensitivity of 0.91, and specificity of 0.86. In the second step, the proteomic profile distinguished the DLB from PD groups with a diagnostic accuracy of 0.92, sensitivity of 0.94, and specificity of 0.88. Discussion: These data provide evidence of the potential utility of a multitiered blood-based proteomic screening method for detecting DLB and distinguishing DLB from PD.

Original languageEnglish (US)
Pages (from-to)270-276
Number of pages7
JournalAlzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volume11
DOIs
StatePublished - Dec 1 2019

Fingerprint

Lewy Body Disease
Proteomics
Parkinson Disease
Dementia
Sensitivity and Specificity
Movement Disorders
Neurology
Alzheimer Disease
Control Groups

Keywords

  • Biomarker screening
  • Blood biomarkers
  • Dementia with Lewy bodies
  • Detection
  • Diagnostic accuracy
  • Parkinson's disease
  • Proteomics

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

A proteomic signature for dementia with Lewy bodies. / O'Bryant, Sid E.; Ferman, Tanis Jill; Zhang, Fan; Hall, James; Pedraza, Otto D; Wszolek, Zbigniew K; Como, Tori; Julovich, David; Mattevada, Sravan; Johnson, Leigh A.; Edwards, Melissa; Graff Radford, Neill R.

In: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 11, 01.12.2019, p. 270-276.

Research output: Contribution to journalArticle

O'Bryant, Sid E. ; Ferman, Tanis Jill ; Zhang, Fan ; Hall, James ; Pedraza, Otto D ; Wszolek, Zbigniew K ; Como, Tori ; Julovich, David ; Mattevada, Sravan ; Johnson, Leigh A. ; Edwards, Melissa ; Graff Radford, Neill R. / A proteomic signature for dementia with Lewy bodies. In: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring. 2019 ; Vol. 11. pp. 270-276.
@article{af3553cad8b34bbcbc5308ced404caee,
title = "A proteomic signature for dementia with Lewy bodies",
abstract = "Introduction: We sought to determine if a proteomic profile approach developed to detect Alzheimer's disease would distinguish patients with Lewy body disease from normal controls, and if it would distinguish dementia with Lewy bodies (DLB) from Parkinson's disease (PD). Methods: Stored plasma samples were obtained from 145 patients (DLB n = 57, PD without dementia n = 32, normal controls n = 56) enrolled from patients seen in the Behavioral Neurology or Movement Disorders clinics at the Mayo Clinic, Florida. Proteomic assays were conducted and analyzed as per our previously published protocols. Results: In the first step, the proteomic profile distinguished the DLB-PD group from controls with a diagnostic accuracy of 0.97, sensitivity of 0.91, and specificity of 0.86. In the second step, the proteomic profile distinguished the DLB from PD groups with a diagnostic accuracy of 0.92, sensitivity of 0.94, and specificity of 0.88. Discussion: These data provide evidence of the potential utility of a multitiered blood-based proteomic screening method for detecting DLB and distinguishing DLB from PD.",
keywords = "Biomarker screening, Blood biomarkers, Dementia with Lewy bodies, Detection, Diagnostic accuracy, Parkinson's disease, Proteomics",
author = "O'Bryant, {Sid E.} and Ferman, {Tanis Jill} and Fan Zhang and James Hall and Pedraza, {Otto D} and Wszolek, {Zbigniew K} and Tori Como and David Julovich and Sravan Mattevada and Johnson, {Leigh A.} and Melissa Edwards and {Graff Radford}, {Neill R}",
year = "2019",
month = "12",
day = "1",
doi = "10.1016/j.dadm.2019.01.006",
language = "English (US)",
volume = "11",
pages = "270--276",
journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",
issn = "2352-8729",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - A proteomic signature for dementia with Lewy bodies

AU - O'Bryant, Sid E.

AU - Ferman, Tanis Jill

AU - Zhang, Fan

AU - Hall, James

AU - Pedraza, Otto D

AU - Wszolek, Zbigniew K

AU - Como, Tori

AU - Julovich, David

AU - Mattevada, Sravan

AU - Johnson, Leigh A.

AU - Edwards, Melissa

AU - Graff Radford, Neill R

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Introduction: We sought to determine if a proteomic profile approach developed to detect Alzheimer's disease would distinguish patients with Lewy body disease from normal controls, and if it would distinguish dementia with Lewy bodies (DLB) from Parkinson's disease (PD). Methods: Stored plasma samples were obtained from 145 patients (DLB n = 57, PD without dementia n = 32, normal controls n = 56) enrolled from patients seen in the Behavioral Neurology or Movement Disorders clinics at the Mayo Clinic, Florida. Proteomic assays were conducted and analyzed as per our previously published protocols. Results: In the first step, the proteomic profile distinguished the DLB-PD group from controls with a diagnostic accuracy of 0.97, sensitivity of 0.91, and specificity of 0.86. In the second step, the proteomic profile distinguished the DLB from PD groups with a diagnostic accuracy of 0.92, sensitivity of 0.94, and specificity of 0.88. Discussion: These data provide evidence of the potential utility of a multitiered blood-based proteomic screening method for detecting DLB and distinguishing DLB from PD.

AB - Introduction: We sought to determine if a proteomic profile approach developed to detect Alzheimer's disease would distinguish patients with Lewy body disease from normal controls, and if it would distinguish dementia with Lewy bodies (DLB) from Parkinson's disease (PD). Methods: Stored plasma samples were obtained from 145 patients (DLB n = 57, PD without dementia n = 32, normal controls n = 56) enrolled from patients seen in the Behavioral Neurology or Movement Disorders clinics at the Mayo Clinic, Florida. Proteomic assays were conducted and analyzed as per our previously published protocols. Results: In the first step, the proteomic profile distinguished the DLB-PD group from controls with a diagnostic accuracy of 0.97, sensitivity of 0.91, and specificity of 0.86. In the second step, the proteomic profile distinguished the DLB from PD groups with a diagnostic accuracy of 0.92, sensitivity of 0.94, and specificity of 0.88. Discussion: These data provide evidence of the potential utility of a multitiered blood-based proteomic screening method for detecting DLB and distinguishing DLB from PD.

KW - Biomarker screening

KW - Blood biomarkers

KW - Dementia with Lewy bodies

KW - Detection

KW - Diagnostic accuracy

KW - Parkinson's disease

KW - Proteomics

UR - http://www.scopus.com/inward/record.url?scp=85062891497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062891497&partnerID=8YFLogxK

U2 - 10.1016/j.dadm.2019.01.006

DO - 10.1016/j.dadm.2019.01.006

M3 - Article

AN - SCOPUS:85062891497

VL - 11

SP - 270

EP - 276

JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

SN - 2352-8729

ER -